REIMAGINE: A central nervous system basket trial showing safety and efficacy of vafidemstat on aggression in different psychiatric disorders
In summary, the REIMAGINE study supports that vafidemstat is safe, well tolerated, and causes a significant and consistent reduction in agitation/aggression and nonaggression features in BPD, ADHD, and ASD. These data support continuing the development of vafidemstat as a new treatment option for these psychiatric disorders.
Authors
- Marc Ferrer (ORCID: https://orcid.org/0000-0002-1283-8578)
- Josep Antoni Ramos‐Quiroga (ORCID: https://orcid.org/0000-0003-1622-0350)
- S. Gutiérrez (ORCID: https://orcid.org/0000-0002-5778-0066)
- Jordi Xaus (ORCID: https://orcid.org/0000-0002-6896-8814)
- Vanesa Richarte (ORCID: https://orcid.org/0000-0001-7327-318X)
- Carlos Buesa (ORCID: https://orcid.org/0000-0001-6293-2514)
- Michael T. Ropacki
- Laura Gisbert (ORCID: https://orcid.org/0000-0002-8329-1717)
- María Isabel Arévalo
- Roger Bullock
Institutions
- Cornell University (US)
- Vall d'Hebron Hospital Universitari (ES)
- Oryzon Genomics (Spain) (ES)
Publication Details
- Journal
- Psychiatry and Clinical Neurosciences
- Published
- 2025-02-12
- DOI
- https://doi.org/10.1111/pcn.13800
- Citations
- 7
- Primary Topic
- Bipolar Disorder and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 10.30
Funders
- Eli Lilly and Company
- Oryzon Genomics
- H. Lundbeck A/S
- Cilag